|
Ipca Laboratories (ICICI securities) Margins to improve, going ahead |
|
Domestic formulation business grows 12% YoY;To clock | 200 crore from institutional generic business in FY12 | Date | Rating | Target Price | Recommendation Price | Broker house | | 2 Aug 2011 | buy (from Hold) | 366 (from 325) | 330 | ICICI securities Report | |
|
Ipca Laboratories (Angel) Results in-line with expectations |
| Date | Rating | Target Price | Recommendation Price | Broker house | | 2 Aug 2011 | accumulate | 358 | 330 | Angel Report | |
|
Ipca Laboratories (Emkay) Booming export formulations – Maintain Buy |
|
Future growth drivers | Date | Rating | Target Price | Recommendation Price | Broker house | | 1 Aug 2011 | buy | 409 | 328 | Emkay Report | |
|
Ipca Laboratories (HSBC) Where mid-caps have an edge |
|
Mid-caps thrive on Indian domestic growth and emerging markets | Date | Rating | Target Price | Recommendation Price | Broker house | | 17 Jun 2011 | neutral;(Initiation) | 407 | -- | HSBC Report | |
|
ipca labs (HDFCSec) Q4FY11 Result Update |
|
ipca laboratories (ICICIsec) Ipca Laboratories |
|
ipca laboratories (Angel) Results above expectations |
|
ipca laboratories (Emkay) Good Growth Ahead, Attractive Valuations - Upgrade to Buy |
|
ipca laboratories (Emkay) Cost overhang dents profitability |
|
ipca laboratories (ICICIsec) Margin pressure but outlook good |
